Trial of Levofloxacin as Prophylaxis After Allogeneic Stem Cell Transplantation (SCT)
Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial With Levofloxacin as Prophylaxis for Bacterial Infections in Immunocompromised Patients After Allogeneic Transplantation of Hematopoietic Stem Cells
1 other identifier
interventional
N/A
1 country
1
Brief Summary
The purpose of this study is to evaluate the efficacy of levofloxacin to prevent bacterial infections in the postneutropenic period in patients who have undergone allogeneic stem cell transplantation (SCT).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 15, 2005
CompletedFirst Posted
Study publicly available on registry
September 22, 2005
CompletedNovember 30, 2007
February 1, 2004
September 15, 2005
November 29, 2007
Conditions
Interventions
Eligibility Criteria
You may qualify if:
- Allogeneic SCT
- Postneutropenic period
- Written consent
You may not qualify if:
- Fever
- Antibiotic therapy
- Neutropenia
- Refusal by the patient
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Charite, CBF
Berlin, State of Berlin, 12200, Germany
MeSH Terms
Conditions
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Igor Wolfgang Blau, Dr.
Charite, CBF, Berlin, Germany
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
September 15, 2005
First Posted
September 22, 2005
Last Updated
November 30, 2007
Record last verified: 2004-02